A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression
Introduction: Muscle-specific kinase (MuSK)- myasthenia gravis (MG) is caused by pathogenic autoantibodies against MuSK that correlate with disease severity and are predominantly of the IgG4 subclass. The first-line treatment for MuSK-MG is general immunosuppression with corticosteroids, but the eff...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Frontiers Media
2024
|
| _version_ | 1811140126092296192 |
|---|---|
| author | Koneczny, I Mané-Damas, M Zong, S De Haas, S Huda, S van Kruining, D Damoiseaux, J De Rosa, A Maestri, M Guida, M Molenaar, P Van Damme, P Fichtenbaum, A Perkmann, T De Baets, M Lazaridis, K Zouvelou, V Tzartos, S Ricciardi, R Losen, M Martinez-Martinez, P |
| author_facet | Koneczny, I Mané-Damas, M Zong, S De Haas, S Huda, S van Kruining, D Damoiseaux, J De Rosa, A Maestri, M Guida, M Molenaar, P Van Damme, P Fichtenbaum, A Perkmann, T De Baets, M Lazaridis, K Zouvelou, V Tzartos, S Ricciardi, R Losen, M Martinez-Martinez, P |
| author_sort | Koneczny, I |
| collection | OXFORD |
| description | Introduction: Muscle-specific kinase (MuSK)- myasthenia gravis (MG) is caused by pathogenic autoantibodies against MuSK that correlate with disease severity and are predominantly of the IgG4 subclass. The first-line treatment for MuSK-MG is general immunosuppression with corticosteroids, but the effect of treatment on IgG4 and MuSK IgG4 levels has not been studied. Methods: We analyzed the clinical data and sera from 52 MuSK-MG patients (45 female, 7 male, median age 49 (range 17–79) years) from Italy, the Netherlands, Greece and Belgium, and 43 AChR-MG patients (22 female, 21 male, median age 63 (range 2–82) years) from Italy, receiving different types of immunosuppression, and sera from 46 age- and sex-matched non-disease controls (with no diagnosed diseases, 38 female, 8 male, median age 51.5 (range 20–68) years) from the Netherlands. We analyzed the disease severity (assessed by MGFA or QMG score), and measured concentrations of MuSK IgG4, MuSK IgG, total IgG4 and total IgG in the sera by ELISA, RIA and nephelometry. Results: We observed that MuSK-MG patients showed a robust clinical improvement and reduction of MuSK IgG after therapy, and that MuSK IgG4 concentrations, but not total IgG4 concentrations, correlated with clinical severity. MuSK IgG and MuSK IgG4 concentrations were reduced after immunosuppression in 4/5 individuals with before-after data, but data from non-linked patient samples showed no difference. Total serum IgG4 levels were within the normal range, with IgG4 levels above threshold (1.35g/L) in 1/52 MuSK-MG, 2/43 AChR-MG patients and 1/45 non-disease controls. MuSK-MG patients improved within the first four years after disease onset, but no further clinical improvement or reduction of MuSK IgG4 were observed four years later, and only 14/52 (26.92%) patients in total, of which 13 (93.3%) received general immunosuppression, reached clinical remission. Discussion: We conclude that MuSK-MG patients improve clinically with general immunosuppression but may require further treatment to reach remission. Longitudinal testing of individual patients may be clinically more useful than single measurements of MuSK IgG4. No significant differences in the serum IgG4 concentrations and IgG4/IgG ratio between AChR- and MuSK-MG patients were found during follow-up. Further studies with larger patient and control cohorts are necessary to validate the findings. |
| first_indexed | 2024-09-25T04:17:01Z |
| format | Journal article |
| id | oxford-uuid:60fc8b2a-debc-48aa-a541-3cd25af8eaac |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-09-25T04:17:01Z |
| publishDate | 2024 |
| publisher | Frontiers Media |
| record_format | dspace |
| spelling | oxford-uuid:60fc8b2a-debc-48aa-a541-3cd25af8eaac2024-07-20T15:09:07ZA retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppressionJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:60fc8b2a-debc-48aa-a541-3cd25af8eaacEnglishJisc Publications RouterFrontiers Media2024Koneczny, IMané-Damas, MZong, SDe Haas, SHuda, Svan Kruining, DDamoiseaux, JDe Rosa, AMaestri, MGuida, MMolenaar, PVan Damme, PFichtenbaum, APerkmann, TDe Baets, MLazaridis, KZouvelou, VTzartos, SRicciardi, RLosen, MMartinez-Martinez, PIntroduction: Muscle-specific kinase (MuSK)- myasthenia gravis (MG) is caused by pathogenic autoantibodies against MuSK that correlate with disease severity and are predominantly of the IgG4 subclass. The first-line treatment for MuSK-MG is general immunosuppression with corticosteroids, but the effect of treatment on IgG4 and MuSK IgG4 levels has not been studied. Methods: We analyzed the clinical data and sera from 52 MuSK-MG patients (45 female, 7 male, median age 49 (range 17–79) years) from Italy, the Netherlands, Greece and Belgium, and 43 AChR-MG patients (22 female, 21 male, median age 63 (range 2–82) years) from Italy, receiving different types of immunosuppression, and sera from 46 age- and sex-matched non-disease controls (with no diagnosed diseases, 38 female, 8 male, median age 51.5 (range 20–68) years) from the Netherlands. We analyzed the disease severity (assessed by MGFA or QMG score), and measured concentrations of MuSK IgG4, MuSK IgG, total IgG4 and total IgG in the sera by ELISA, RIA and nephelometry. Results: We observed that MuSK-MG patients showed a robust clinical improvement and reduction of MuSK IgG after therapy, and that MuSK IgG4 concentrations, but not total IgG4 concentrations, correlated with clinical severity. MuSK IgG and MuSK IgG4 concentrations were reduced after immunosuppression in 4/5 individuals with before-after data, but data from non-linked patient samples showed no difference. Total serum IgG4 levels were within the normal range, with IgG4 levels above threshold (1.35g/L) in 1/52 MuSK-MG, 2/43 AChR-MG patients and 1/45 non-disease controls. MuSK-MG patients improved within the first four years after disease onset, but no further clinical improvement or reduction of MuSK IgG4 were observed four years later, and only 14/52 (26.92%) patients in total, of which 13 (93.3%) received general immunosuppression, reached clinical remission. Discussion: We conclude that MuSK-MG patients improve clinically with general immunosuppression but may require further treatment to reach remission. Longitudinal testing of individual patients may be clinically more useful than single measurements of MuSK IgG4. No significant differences in the serum IgG4 concentrations and IgG4/IgG ratio between AChR- and MuSK-MG patients were found during follow-up. Further studies with larger patient and control cohorts are necessary to validate the findings. |
| spellingShingle | Koneczny, I Mané-Damas, M Zong, S De Haas, S Huda, S van Kruining, D Damoiseaux, J De Rosa, A Maestri, M Guida, M Molenaar, P Van Damme, P Fichtenbaum, A Perkmann, T De Baets, M Lazaridis, K Zouvelou, V Tzartos, S Ricciardi, R Losen, M Martinez-Martinez, P A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression |
| title | A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression |
| title_full | A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression |
| title_fullStr | A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression |
| title_full_unstemmed | A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression |
| title_short | A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression |
| title_sort | retrospective multicenter study on clinical and serological parameters in patients with musk myasthenia gravis with and without general immunosuppression |
| work_keys_str_mv | AT konecznyi aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT manedamasm aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT zongs aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT dehaass aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT hudas aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT vankruiningd aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT damoiseauxj aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT derosaa aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT maestrim aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT guidam aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT molenaarp aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT vandammep aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT fichtenbauma aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT perkmannt aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT debaetsm aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT lazaridisk aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT zouvelouv aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT tzartoss aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT ricciardir aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT losenm aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT martinezmartinezp aretrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT konecznyi retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT manedamasm retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT zongs retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT dehaass retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT hudas retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT vankruiningd retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT damoiseauxj retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT derosaa retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT maestrim retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT guidam retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT molenaarp retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT vandammep retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT fichtenbauma retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT perkmannt retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT debaetsm retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT lazaridisk retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT zouvelouv retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT tzartoss retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT ricciardir retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT losenm retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression AT martinezmartinezp retrospectivemulticenterstudyonclinicalandserologicalparametersinpatientswithmuskmyastheniagraviswithandwithoutgeneralimmunosuppression |